| 1981 |
Francesco De Santis' entry as Italfarmaco’s Managing Director, the family company, led by his father Prof. Gastone De Santis (President) in the Fulvio Testi branch. |
| 1982 |
Italfarmaco’s first product “Selezen” (imidazate) is introduced on the market. |
| 1983 |
Acquisition of the majority of LPB shares and requalification of the research laboratories at the LPB office in Cinisello Balsamo with relocation of the research staff. |
| 1984 |
Acquisition of CHEMI Spa by Italfarmaco (Chemi becomes a subsidiary company involved in the production and marketing of semi finished and finished chemical products). Founded in 1973, the new plant in Patrica (FR) is inaugurated in 1974. |
| 1985 |
Francesco De Santis takes on the position of Director of the Board of Italfarmaco Spa. |
| 1986 |
Market launch of Nicardal 20 (hypertensive). |
| 1987 |
Francesco De Santis member of Farmadustria Council (Italfarmaco and Lifepharma were already associated partners since 1978).
Francesco De Santis takes on the position of President of Italfarmaco Spa. |
| 1988 |
Market launch of Ferplex (Ferrous proteinsuccinilate) manufactured by Italfarmco research laboratory. |
| 1989 |
Market launch of Gliatilin, manufactured by Italfarmaco research laboratory (choline alfoscerate). |
| 1990 |
Francesco De Santis is awarded on the behalf of Italfarmaco the U.N.A.M.S.I. “Carlo Guidetti” prize for researchers, representatives of praiseworthy firms in medical scientific communication. |
 |
| Inauguration of the production installation of alpha-Glycerophosphorylcholine in the Chemi manufacturing plant in Patrica (FR). |
| 1991 |
Francesco De Santis gets the foundation of Italfarmaco SA Spain underway (with a production plant which manufactures oral liquids and focuses on the respiratory therapeutic areas, cardiovascular and gynaecologic).
CHEMI opens a waste water treatment plant (with high technological quality and importance for environmental protection of the site). |
| 1992 |
Francesco De Santis is appointed President of Tecnofarmaci (business consortium for pharmaceutical research). |
| 1993 |
Italfarmaco obtains acknowledgement for national funding of several research projects. |
| 1994 |
The Italfarmaco’s research development goes on. The research results of ILOPROST (prostanoide) and CALCIPARINA (antithrombotic) anticoagulants for preventive treatment of severe peripheral arterial diseases are published. |
| 1995 |
Foundation of Italfarmaco Holding Spa, Francesco De Santis assumes the position of President.
Introduction of one of the company’s top product “Myelostim" (lenograstim: growth factors Granolicite-Colony Stimulating Factor) thanks to the partnership with the Japanese firm CHUGAI. Italfarmaco markets in 2009 “Granocyte” manufactured by Chugai. |
| 1996 |
Foundation of Laboratorios Farmaceutico Logogen SA (Spain) - second commercial line of Italfarmaco SA Spain |
| 1997 |
Acquisition of Lifepharma – (Milan: acquisition) - sale of drugs mainly targeting foreign markets such as the Middle East and North Africa.
Italfarmaco Spa transfers its commercial offices and administrative branch in Cinisello Balsamo. In the Milan manufacturing plant located at 330 Viale Fulvio Testi are expanded production lines and logistic facilities.
In that same year, Italfarmaco SA Spain establishes its third commercial line: Laboratorios Framaceutico Valomed SA (Spain). |
| 1998 |
Foundation of ITF Farma Chile SA in Santiago, which deals completely with commercial activities. |
| 1999 |
Opening of the ITF representative office in Russia (based in Moscow. Start up operations in Giorgia and Azebaijan).
Foundation of ITF Farma Produtos Farmaceutico Lda Portuguese branch office of Italfarmaco S.A. based in Barcarena-Lisbon. The office deals completely with commercial activities. |
| 2000 |
ITF Chemical Ltda, Brazil (chemical production based in Camacari/S. de Bahia) and opening ceremony of the plant in 2001. |
 |
| 2001 |
A new company in the group is founded: Chemi Nutraeuticals, USA.
Foundation of Italfarmaco Hellas, in Athens which markets gynaecologic and neurologic products.
Italfarmaco launches the chemotherapy product MUPHORAN (fotemustine). |
| 2002 |
Foundation of ITF Medigen Produtos Farmaceutico Lda (Portugal): a commercial line linked with Italfarmaco SA. |
| 2003 |
Acquisition of shares from Effik – France (Effik group, active in Italy, Portugal and Spain (and then in Switzerland) which is specialized in the gynaecological field, with contraceptive products, substitutive hormonal treatments for menopause, sterility and acne). |
| 2004 |
Foundation of Laboratorios Farmaceuticos Medilab SA (Spain) – a company which performs medical diagnostic activities.
Italfarmaco Milan gets the FDA Certification for the production of sterilized pre-filled syringes.
Foundation of CHEMI LLC. |
| 2005 |
Italfarmaco completes the acquisition of ITF Farma Chile SA.
Italfarmaco Italia launches VASEXTEN (barnidipine) antihypertensive. |
| 2006 |
Foundation of ITF – Medical Produtos Farmaceuticos Lds (Portugal) – which incorporates two commercial lines from ITF Portugal.
Italfarmaco launches ALOXI (palonosetron) antiemetic for tumoral chemotherapy. |
| 2007 |
Francesco De Santis inaugurates Italfarmaco Spa new Business Unit Ginecologica (which joins the immunocologic and vascular line already active in the company).
FDA confirms certification for the manufacturing plant. Focus inspection: sterilized pre-filled syringes for Epinefrine.
The prize for Best sales Growth at the Aloxi Awards is conferred to Italfarmaco. |
| 2008 |
The first data concerning the use/development of a new conditioning scheme of the peripheral stem cell transplant with fotemustina (alchiant agent) are registered. The previous regimen for marrow pre-transplant was implemented by a “beam” scheme (with the use of carmustina an alchilante agent) but now the “feam” regimen using fotemustina is employed. |
| 2009 |
Acquisition of Instituto Farmaceutico Labomed SA (based in Santiago, it deals with commercial and productive activities) and merger with ITF Farma Chile SA in ITF – Labomed Farmaceutica Limitada.
In the same year, the Turkey representative office opens: ITF ILAC. |
| 2010 |
Versalya SA (Morocco) is founded.
Italfarmaco Italia in 2009 and 2010 (with Pletal, Zarelis and Saforelle) markets the largest number of products (Natecal Oro, Fentalgon, Treoject, Natalben più, Inofert).
FDA certification renewal for the production plant Italfarmaco. Focus inspection: sterilized pre-filled syringes for Octreotide e Enoxaparina.
FDA Inspection CHEMI (Cinisello). Focus inspection: Octreotice Acetate.
FDA Inspection CHEMI (Patrica): Focus inspection: Enoxaparina. |
| 2011 |
Ferplex Fol and Sonirem are launched on Italian markets.
ANVISA inspection on the Brazilian Italfarmaco premises: successful outcome with GMP certification expected in August.
Italfarmaco SA Spain celebrates its twenty years of operations. |
| 2012 |
Italfarmaco Group’s consolidation in Scandinavian countries.
Italfarmaco Italia markets new products: Gelistrol, Zaredrop, Folifill. |
| 2013 |
Francesco De Santis has relected Vice-President of Farmindustria for the two-year period 2013-2015
| Italfarmaco achieves the Best Poster Critics Choice’s Award at the "Aloxi ten years of Marketing celebration" event by Helsinn Healthcare SA |
 |
28 novembre - Sevelamer New Plant Inauguration by ITF Chemical (Bahia –Brasil) (Sevelamer is a treatment for the chronic renal impairment). |
| 2014 |
| June - Inauguration new Office Italfarmaco Moscow. |
 |
June - FDA approval for Enoxaparin ANDA by Teva, partner of Chemi (production starts at Italfarmaco’s plant in Milan).
December - Acquisition of Edwards Pharmaceuticals Inc. by our affiliate, Women’s Choice Pharmaceuticals, LLC, in the U.S.
Market launch of Xarenel (cholecalciferol), Coripren (lercanidipine + enalapril), Zenaus (ginger-based supplement), Teglutik (riluzole), Inofert (inositol-based supplement). |
| 2015 |
July - GMP approval by the Turkish Authorities after the inspection of the production plant Italfarmaco in Milan.
Market Launch of AINARA (medical device carbopol+policarbophil-based).
September - Opening of the Italfarmaco Group representative office in Vietnam.
September - Italfarmaco Group announce the acquisition of the remaining 50% in Effik, S.A. |
| 2016 |
| January - Madrid, Italfarmaco Spain celebrates 25 years. |
 |
|
| |
| 2-3 March - Market launch of Akynzeo, new NK-1 antagonist serotonergic (combination of Palonosetron + netupitant) in fixed-dose oral formulation. |
 |
|
| |
 |
| |
September - Launch of Flavia: supplement of women in menopause. |
| |
September – October - Two launches in the Primary Care of Italfarmaco: Gliatilin with new vials (area of the Central Nervous System) and the Filifill120 tablets with new dosage (Cardiovascular area). |
| 2017 |
May - Natalben Oro and Natalben Supra launches expand the range of multivitamin and multimineral supplements designed for pregnancy. |
| 2018 |
| January - Athens Greece, ITF Hellas celebrates 20 years. |
 |
|
| |
September - ITF PHARMA announces FDA approval of TIGLUTIK™ (riluzole) oral suspension for the tratment of amyotrophic lateral sclerosis (ALS). |
| |
September - New Marketing launch of SONIDOR, a food supplement based on hawthorn, lavender and hops extracts that induce sleep and relaxation. |
| 2019 |
January - Italfarmaco strengthen its presence in rare disease area by launching the medicinal product VOTUBIA. |
| |
February - Italfarmaco launches NUPERAL in Italy, the first drug as fixed combination of doxilamine succinate and pyridoxine hydrochloride authorized for the symptomatic treatment of nausea and vomiting during pregnancy. |